BioSpace News Archive

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has filed an amended Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA).

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”).

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613 ® (devimistat), for the treatment of acute myeloid leukemia (AML). “Receiving Fast Track designation, especially during a pandemic that has created significant challenges

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced a comprehensive restructuring plan designed to further reduce its cost base and right size its organization. “To adapt to the current market environment and maximize shareholder value, we are refocusing and substantially reducing our operating footprint, which is expected to result in significant cost savings,” said Arthur Higgins, Chairman of Assertio. “G

- SARS-CoV-2 IgG II Quant antibody test measures levels of IgG antibodies to help measure and understand a person’s immune response - The test specifically identifies levels of IgG antibodies that attach to the virus’ spike protein which can be helpful to evaluate a person’s immune response to vaccines

The Muscular Dystrophy Association (MDA) today released Frequently Asked Questions (FAQs) on the COVID-19 vaccines specifically for the neuromuscular disease (NMD) community the organizations serves. MDA continues to advocate for priority COVID-19 vaccine access for people living with muscular dystrophy, ALS, and related neuromuscular diseases.

Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital,

VectivBio Holding AG , a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointment of Sandip Kapadia to its Board of Directors.

ENPICOM BV, an innovative bioinformatics software engineering company, and MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, announced a strategic partnership to enable efficient MiXCR integration into ENPICOM’s cloud-based IGX Platform

BERG announced a research collaboration with AdventHealth, a leading non-profit healthcare system, to conduct a comprehensive study on various age-related metabolic, neurological and musculoskeletal disorders, including sarcopenia and Non-Alcoholic Steatohepatitis.